Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effect of a Weekly Yoga Program Integrated Into Standard Care on Disease Activity, Fatigue, Mood, and Treatment Adherence in Patients With Systemic Autoimmune and Inflammatory Diseases: A Prospective Observational Study (YOGAMID)

29. Juni 2026 aktualisiert von: Assistance Publique - Hôpitaux de Paris

"Systemic autoimmune and inflammatory diseases (SAIDs) are chronic disorders associated with substantial impairment in quality of life, largely due to persistent fatigue, chronic pain, and mood disorders. Fatigue affects more than two-thirds of patients with systemic autoimmune diseases, particularly those with systemic lupus erythematosus (SLE), and is one of the major determinants of health-related quality of life. Fatigue has also been associated with suboptimal treatment adherence.

Mind-body interventions, including yoga, have demonstrated beneficial effects on fatigue, mood, and quality of life in several systemic autoimmune and inflammatory diseases. In patients with SLE, previous studies suggest that appropriately adapted physical activity is safe and may improve functional outcomes without increasing the risk of disease flares. Improving non-specific symptoms such as fatigue, pain, and mood disorders may also contribute to better treatment adherence, which is essential for long-term disease control.

However, real-world data on the overall impact of yoga integrated into routine clinical care on disease activity and treatment adherence remain limited. This prospective observational study aims to evaluate the association between participation in a 12-session weekly yoga program delivered as part of standard care and changes in clinical outcomes among adults with systemic autoimmune and inflammatory diseases, predominantly systemic lupus erythematosus, followed in the Internal Medicine Department of Bichat-Claude Bernard Hospital.

The study will assess changes in disease activity using disease-specific validated activity indices (including SELENA-SLEDAI for patients with SLE), fatigue, pain intensity, depressive symptoms, and health-related quality of life. Treatment adherence will be evaluated by whole-blood hydroxychloroquine concentrations obtained as part of routine clinical care. The frequency of disease flares and disease-related emergency department visits during follow-up will also be recorded.

Participants will be enrolled over a 6-month period and followed for 6 months, which corresponds to routine clinical follow-up and allows assessment of clinically meaningful changes during and after the 3-month yoga program."

Studienübersicht

Status

Noch keine Rekrutierung

Intervention / Behandlung

Detaillierte Beschreibung

"Background

Systemic autoimmune and inflammatory diseases (SAIDs) are chronic disorders associated with substantial impairment in health-related quality of life. Persistent fatigue, chronic pain, and mood disorders are among the most burdensome manifestations and remain insufficiently controlled despite advances in pharmacological treatment. Fatigue is particularly common in patients with systemic lupus erythematosus (SLE), affecting more than two-thirds of patients, and has been associated with reduced quality of life and poorer treatment adherence.

Mind-body interventions, including yoga, have demonstrated beneficial effects on fatigue, psychological well-being, and quality of life in several chronic inflammatory diseases. In patients with SLE, adapted physical activity has been shown to be safe and is not associated with an increased risk of disease flares. Improving non-specific symptoms such as fatigue, pain, and mood disorders may also enhance long-term adherence to treatment, an essential component of disease management.

Although yoga is increasingly offered as a complementary intervention in routine clinical practice, evidence regarding its overall impact on disease activity, patient-reported outcomes, and treatment adherence in real-world settings remains limited.

Study Rationale

The purpose of this prospective observational study is to evaluate the association between participation in a weekly yoga program integrated into routine care and clinical outcomes in adults with systemic autoimmune and inflammatory diseases, predominantly systemic lupus erythematosus. Because the yoga program is part of standard care, no study-specific intervention will be assigned.

Study Population

The study will include adults (≥18 years) with a diagnosis of a systemic autoimmune or inflammatory disease, predominantly systemic lupus erythematosus, who are followed in the Department of Internal Medicine at Bichat-Claude Bernard Hospital. Eligible participants will have stable disease or low disease activity and will voluntarily participate in the weekly yoga program offered as part of routine care.

Study Design

This is a single-center, prospective observational study conducted in a real-world clinical setting. Participants enrolled in the study will attend a standardized weekly yoga program consisting of 12 sessions over a 3-month period while continuing their usual medical management. Clinical and biological data routinely collected during standard follow-up visits will be recorded prospectively. Participants will be followed for 6 months, allowing assessment of changes occurring during and after completion of the yoga program.

The planned recruitment period is 6 months, which is expected to provide an adequate sample of eligible patients receiving routine care in the study center."

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

100

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The target population consists of adults with systemic autoimmune and inflammatory diseases (SAIDs), predominantly systemic lupus erythematosus (SLE), who receive routine follow-up in the Department of Internal Medicine at Bichat-Claude Bernard Hospital. This population is particularly affected by chronic fatigue and mood disorders, making it an appropriate population in which to evaluate the potential benefits of a mind-body intervention such as yoga.

Beschreibung

Inclusion Criteria:

Adults aged 18 years or older. Diagnosis of a systemic autoimmune or inflammatory disease established according to the current internationally accepted classification criteria for the specific disease.

Stable disease or low disease activity at the time of enrollment. Receiving regular follow-up in the Department of Internal Medicine at Bichat-Claude Bernard Hospital.

Exclusion Criteria:

Severe disease flare requiring a major change in treatment at the time of enrollment.

Medical contraindication to gentle physical activity. Refusal to participate in the study after receiving study information."

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
control group
The control group will include patients with a systemic autoimmune or inflammatory disease receiving routine care who do not participate in the weekly yoga program and do not receive any structured therapeutic education or psychological support intervention during the study period
YOGA group
Participants in the yoga group will participate in a 12-session weekly yoga program integrated into routine clinical care while continuing their usual medical management for systemic autoimmune and inflammatory diseases
12-session weekly yoga program integrated into routine clinical care

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
To evaluate the change in disease activity, assessed using validated disease-specific clinical activity indices routinely used in clinical practice (e.g., SELENA-SLEDAI for systemic lupus erythematosus).
Zeitfenster: 6 month
6 month

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
To describe changes in fatigue over the course of follow-up
Zeitfenster: 6 month
as assessed using PICOT fatigue scale.
6 month
To describe changes in pain during follow-up
Zeitfenster: 6 month
as assessed using a visual analogue scale (VAS)
6 month
To describe changes in depressive symptoms during follow-up
Zeitfenster: 6 month
as assessed using the Hospital Anxiety and Depression Scale (HADS)
6 month
To describe changes in health-related quality of life during follow-up
Zeitfenster: 6 month
as assessed using the 36-Item Short Form Health Survey (SF-36)
6 month
To describe changes in adherence to hydroxychloroquine treatment during follow-up
Zeitfenster: 6 month
as assessed by whole-blood hydroxychloroquine concentrations
6 month
Number of disease flares during the follow-up period
Zeitfenster: 6 month
6 month
Number of disease-related emergency department visits during the follow-up period
Zeitfenster: 6 month
6 month

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Tiphaine Goulenok, MD, Assistance Publique - Hopitaux de Paris

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Juli 2026

Primärer Abschluss (Geschätzt)

1. Januar 2027

Studienabschluss (Geschätzt)

1. August 2027

Studienanmeldedaten

Zuerst eingereicht

29. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. Juni 2026

Zuerst gepostet (Tatsächlich)

6. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

29. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • APHP260560
  • 2026-A00913-48 (Andere Kennung: ID-RCB)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Systemic Autoimmune and Inflammatory Diseases

Klinische Studien zur yoga program

3
Abonnieren